This clinical trial is focused on studying a condition known as Pulmonary Arterial Hypertension (PAH). PAH is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. The study includes various forms of PAH, such as idiopathic PAH, which occurs without a known cause, heritable PAH, which is passed down through families, and PAH that is associated with other conditions like connective tissue disease, HIV infection, or congenital heart disease. The treatment being tested in this study is called MK-5475, which is administered as an inhalation powder. The study also involves a comparison with a placebo to evaluate the effectiveness and safety of MK-5475.

The purpose of the study is to assess how well MK-5475 works in reducing the resistance in the blood vessels of the lungs and improving the distance participants can walk in six minutes. The study is divided into two phases. In the first phase, the focus is on the change in pulmonary vascular resistance, which is a measure of the pressure in the lung arteries, after 12 weeks of treatment. In the second phase, the study looks at the change in the six-minute walk distance after 12 weeks and again after 24 weeks. Participants will be randomly assigned to receive either MK-5475 or a placebo, and neither the participants nor the researchers will know who is receiving which treatment until the study is completed.

Throughout the study, participants will be monitored for any side effects or adverse events. The study aims to provide valuable information on the potential benefits and risks of using MK-5475 for treating PAH. This research could lead to new treatment options for individuals living with this challenging condition.